Project Grant R41GM154562

Award Date 7/1/24
Completion Date 6/30/25
Dollars Obligated $2
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), aims to develop novel non-viral gene delivery methods that are less expensive and safer than lentiviral vectors for cell therapies. The $364,167 award, spanning from Sep 1, 2024 to Aug 31, 2027, supports a collaborative research effort led by Villanova University. The key objectives are to: 1) develop novel polymeric gene delivery...
This Project Grant awarded by the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training) to Physical Sciences Inc. (PSI) provides $302,417 to develop a novel in-line biomanufacturing process analytical technology tool. The tool enables real-time monitoring of biomolecules in large-scale bioreactors used for gene therapy viral vector production. The project, which runs from Sep 1, 2024 to Aug 31, 2025, involves collaboration with the University of...
This $325,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) will support the development and testing of a new class of programmable, non-viral gene therapy carriers and cargo known as virus-inspired DNA origami (VIDO) vectors and repair templates. The project aims to demonstrate that VIDO vectors can effectively encapsulate and co-deliver CRISPR-Cas9 gene editing agents and repair...
The federal Project Grant award of $5,037,617 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports Chromatan Inc.'s development and scale-up of its Continuous Countercurrent Tangential Chromatography (CCTC) platform for the purification of recombinant adeno-associated virus (rAAV) vectors used in gene therapies. The key objectives of this project are to: 1) develop a comprehensive process development toolkit...
This federal Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports the development and validation of Synvivia, Inc.'s platform for optimizing the yield and quality of therapeutic adeno-associated virus (AAV) vector manufacturing. The $1,640,169 award will fund Synvivia's efforts to: 1) demonstrate that their cyclic peptide discovery library contains members that can improve...
The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...
This Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research Federal Grant Program (CFDA 93.395), aims to develop a gene therapy vector using the adeno-associated virus (AAV) system for treating Kaposi's sarcoma-associated herpesvirus (KSHV)-related malignancies. The key products and services to be delivered through this $188,169 award include: Conducting proof-of-concept studies to evaluate the biological activity and efficacy of the AAV-based gene...
Through a $1,000,000 Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, Optimeos Life Sciences, Inc., a for-profit biotechnology company, is developing a non-viral platform for delivering mRNA-based gene therapies. The project aims to validate a polymer-lipid hybrid formulation that can safely and repeatedly deliver genetic instructions to patients with rare urea cycle disorders, overcoming limitations of current...
This federal Project Grant award for $354,807.00, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), aims to pioneer advanced delivery and targeting strategies to overcome biological barriers in re-delivering adeno-associated virus (AAV) gene therapy vectors. The project encompasses three distinct delivery platforms to address key challenges in AAV gene therapy, including: 1) Targeted delivery of...
This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

VECTORLESS SUPERCOILED DNA: A NEW SCALABLE ABACTERIAL IN VITRO SYSTEM TO IMPROVE GENE THERAPY SAFETY AND PRODUCTION EFFICIENCY - PROJECT SUMMARY/ ABSTRACT BACTERIAL PLASMID MANUFACTURE IS NOW A MAJOR BOTTLENECK IN VIRAL GENE THERAPY PRODUCTION WORKFLOWS. ALTHOUGH SUPERCOILED PLASMID-BASED VECTORS ARE THE CURRENT INDUSTRY STANDARD FOR TRANSIENT TRANSFECTION OF PACKAGING CELLS, MINIMIZED DNAS OFFER SUBSTANTIAL SAFETY AND EFFICIENCY ADVANTAGES. CURRENTLY, THERE IS A DEARTH OF TECHNOLOGIES TO PRODUCE PACKAGING AND PAYLOAD DNAS IN A COMPLETELY SYNTHETIC, ABACTERIAL MANNER. IN FACT, NO MINIMIZED DNA TECHNOLOGY CAPABLE OF SCALABLE SYNTHETIC PRODUCTION OF SUPERCOILED AND COMPLETELY SCARLESS DNAS EXISTS. SUPERCOILING IS THE PREFERRED TOPOLOGY FOR CIRCULAR DNAS GIVEN THAT THEIR PERFORMANCE IN TRANSIENT TRANSFECTIONS IS SUPERIOR TO OTHER DNA FORMS. MINICIRCLES OR MINIVECTORS GENERATED BY RECOMBINATION IN BACTERIA ARE SUPERCOILED BUT REQUIRE EXTENSIVE AND EXPENSIVE PURIFICATION AND YIELD A FINAL PRODUCT 'SCARRED' BY A VARIABLE LENGTH PROKARYOTIC SEQUENCE. DOGGYBONE DNAS (DBDNAS) COMPRISED OF LINEAR DOUBLE STRANDED DNA WITH CIRCULARIZED SINGLE-STRANDED ENDS ARE PRODUCED SYNTHETICALLY BUT ARE NOT SUPERCOILED. THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP AN EFFICIENT BACTERIA- INDEPENDENT WORKFLOW TO PRODUCE, AT A COMMERCIALLY VIABLE SCALE, COMPLETELY VECTORLESS SUPERCOILED DNAS (VLSDNAS). THIS WILL BE ACHIEVED USING A NEW DNA ASSEMBLY TECHNOLOGY WE HAVE DEVELOPED TERMED CYCLIC HETERODUPLEX THERMOSTABLE LIGATION ASSEMBLY (CHTLA). THE OBJECTIVES OF THE WORK PROPOSED HERE ARE TO 1) OPTIMIZE CHTLA REACTION CONDITIONS TO MAXIMIZE SUPERCOIL PRODUCTION AND ELIMINATE BYPRODUCTS; AND 2) TO PRODUCE VLSDNAS ENCODING ALL PACKAGING, REPLICATION, AND PAYLOAD COMPONENTS TO GENERATE ADENO-ASSOCIATED VIRUS (AAV) PARTICLES LOADED WITH A GREEN FLUORESCENT PROTEIN (GFP) REPORTER GENE. ROLLING CIRCLE AMPLIFICATION (RCA) OF A STANDARDIZED GREEN FLUORESCENT PROTEIN (GFP) GENE EXPRESSION CASSETTE WILL BE USED TO GENERATE MILLIGRAM QUANTITIES OF OVERLAPPING AND OFFSET DNA PRECURSORS FOR CHTLA REACTIONS. TO MAXIMIZE SUPERCOILING OF CHTLA PRODUCTS, A TWO-ENZYME, ONE-POT SYSTEM WILL BE DEVELOPED CONTAINING BOTH THERMOSTABLE DNA LIGASE AND THERMOSTABLE DNA GYRASE ACTIVITY. THE WORK PROPOSED HERE IS HIGHLY INNOVATIVE BECAUSE IT REPRESENTS A SUBSTANTIAL DEPARTURE FROM THE STATUS QUO BY DEVELOPING A ROBUST NEW TECHNOLOGY TO PRODUCE, ENTIRELY IN VITRO, DNAS WITH A SUPERCOILED TOPOLOGY THAT ARE COMPRISED EXCLUSIVELY OF THE SEQUENCE OF INTEREST. VLSDNA VERSIONS OF PHELPER-KAN, PAAV-REP- CAP, AND PAAV ITR-GFP ENCODING ADENOVIRUS E1A, E1B, E2A, E4 AND VA RNA OPEN READING FRAMES WILL BE GENERATED USING STANDARD AS WELL AS OPTIMIZED CONDITIONS IDENTIFIED IN AIM 1. VLSDNAS WILL BE QUANTITATIVELY COMPARED TO STANDARD BACTERIALLY-SOURCED PHELPER-KAN, PAAV-REP-CAP, AND PAAV ITR- GFP TRIPLE PLASMID TRANSFECTION BY COMMERCIAL COLLABORATOR. UPON COMPLETION OF THESE AIMS WE WILL HAVE DETERMINED OPTIMAL CONDITIONS TO GENERATE FUNCTIONAL VLSDNAS AT A SCALE THAT IS COMMERCIALLY VIABLE. IN PHASE 2, WE WILL SEEK TO FURTHER SCALE PRODUCTION TOWARD THE GRAM+ QUANTITIES THAT WILL BE REQUIRED TO SERVE CUSTOMERS IN THE AAV AND LENTIVIRUS (LV) GENE THERAPY SECTORS.

Posted 6/14/24, 12:00 AM